The authors obtained data from multiple observational epidemiology studies of people with active RA (DAS28>3.2), using baseline and follow-up data from the BSRBR participants (1) commencing anti-TNF therapy (n=10,813), or (2) changing between non-biologic DMARDs (n=2992), (3) Early Rheumatoid Arthritis Network participants (n=813), and (4) participants in a cross-sectional study exploring fibromyalgia and pain thresholds (n=45).27 Derived indices were the proportion of DAS28 attributable to patient-reported components (DAS28-P), tender-swollen difference and tender:swollen ratio. This evidence concerns the gene TNF and rheumatoid arthritis.